Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators
CR Benedict,
DE Johnstone,
DH Weiner,
MG Bourassa,
V Bittner,
R Kay,
P Kirlin,
B Greenberg,
RM Kohn,
JM Nicklas,
et al.
Division of Cardiology, University of Texas Medical School, Houston 77030.
OBJECTIVES. This study examined the relation between neurohumoral activation and severity of left ventricular dysfunction and congestive heart failure in a broad group of patients with depressed left ventricular function who were not recruited on the basis of eligibility for a therapeutic trial. BACKGROUND. Previous studies have established the presence of neurohumoral activation in patients with severe congestive heart failure. It is not known whether the activation of these neurohumoral mechanisms is related to an impairment in left ventricular function. METHODS. From the 6,273 patients recruited into the Studies of Left Ventricular Dysfunction Registry (SOLVD), a subgroup of 859 patients were randomly selected, and their plasma norepinephrine, plasma renin activity, arginine vasopressin and atrial natriuretic peptide levels were correlated with clinical findings, New York Heart Association functional class, left ventricular ejection fraction and drug use. RESULTS. There was a weak but significant correlation between ejection fraction and an increase in plasma norepinephrine (rho = -0.18, p < 0.0001), plasma renin activity (rho = -0.24, p < 0.0001) and arginine vasopressin (rho = -0.12, p < 0.003). The only exception was atrial natriuretic peptide, which showed the best correlation to ejection fraction (rho = -0.37, p < 0.0001). Deterioration in functional class was associated more with increases in atrial natriuretic peptide (p = 0.0003) and plasma renin activity (p = 0.0003) and less with an increase in plasma norepinephrine. Of the clinical variables, elevated jugular venous pressure and third heart sound (S3) gallop were significantly associated with increased levels of plasma norepinephrine, plasma renin activity and atrial natriuretic peptide. We then compared the relation of neurohormones with clinical signs, functional status, ejection fraction and drug therapy and controlled for mutual interactive effects. After adjustment, a decrease in ejection fraction was still significantly related to an increase in plasma norepinephrine, plasma renin activity and atrial natriuretic peptide. In contrast, only a difference between functional classes I and III/IV was associated with an increase in plasma renin activity and atrial natriuretic peptide levels. CONCLUSIONS. Neurohumoral activation in patients with heart failure is related to severity of left ventricular functional depression, and this relation is independent of functional class or concomitant drug therapy.
This article has been cited by other articles:

|
 |

|
 |
 
M. Albaghdadi, M. Gheorghiade, and B. Pitt
Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes
Eur. Heart J.,
November 1, 2011;
32(21):
2626 - 2633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. L. Dini, G. M. Rosa, P. Fontanive, V. Santonato, A. M. Napoli, M. Ciuti, and V. Di Bello
Combining blood flow and tissue Doppler imaging with N-terminal pro-type B natriuretic peptide for risk stratification of clinically stable patients with systolic heart failure
Eur Heart J Cardiovasc Imaging,
May 1, 2010;
11(4):
333 - 340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Turk, P. Varadarajan, A. Kamath, U. Sampat, S. Khandhar, R. Patel, and R. G. Pai
Survival Benefit of Aortic Valve Replacement in Older Patients With Asymptomatic Chronic Severe Aortic Regurgitation
Ann. Thorac. Surg.,
March 1, 2010;
89(3):
731 - 737.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Yamaji, T. Tsutamoto, C. Kawahara, K. Nishiyama, T. Yamamoto, M. Fujii, and M. Horie
Serum Cortisol as a Useful Predictor of Cardiac Events in Patients With Chronic Heart Failure: The Impact of Oxidative Stress
Circ Heart Fail,
November 1, 2009;
2(6):
608 - 615.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bansal, J. Lindenfeld, and R. W. Schrier
Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist?
Circ Heart Fail,
July 1, 2009;
2(4):
370 - 376.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Grassi, G. Bolla, F. Quarti-Trevano, F. Arenare, G. Brambilla, and G. Mancia
Sympathetic activation in congestive heart failure: Reproducibility of neuroadrenergic markers
Eur J Heart Fail,
December 1, 2008;
10(12):
1186 - 1191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. S. Colucci, T. J. Kolias, K. F. Adams, W. F. Armstrong, J. K. Ghali, S. S. Gottlieb, B. Greenberg, M. I. Klibaner, M. L. Kukin, J. E. Sugg, et al.
Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial
Circulation,
July 3, 2007;
116(1):
49 - 56.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. K. Stein, L. Tereshchenko, P. P. Domitrovich, R. E. Kleiger, A. Perez, and P. Deedwania
Diastolic dysfunction and autonomic abnormalities in patients with systolic heart failure
Eur J Heart Fail,
April 1, 2007;
9(4):
364 - 369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Meune, K. Wahbi, Y. Fulla, A. Cohen-Solal, D. Duboc, I. Mahe, G. Simoneau, J.-F. Bergmann, S. Weber, and S. Mouly
Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors
Eur J Heart Fail,
February 1, 2007;
9(2):
197 - 201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Rienstra, I. C. Van Gelder, M. P. Van den Berg, F. Boomsma, and D. J. Van Veldhuisen
Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP
Europace,
July 1, 2006;
8(7):
482 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. K. Teo, L. B. Mitchell, J. Pogue, J. Bosch, G. Dagenais, S. Yusuf, and on behalf of the HOPE Investigators
Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction
Circulation,
September 14, 2004;
110(11):
1413 - 1417.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Menezes Falcao, F. Pinto, L. Ravara, and P. A. van Zwieten
BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction
Journal of Renin-Angiotensin-Aldosterone System,
September 1, 2004;
5(3):
121 - 129.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Latini, S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A. P Maggioni, G. Tognoni, J. N Cohn, et al.
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT
Eur. Heart J.,
February 2, 2004;
25(4):
292 - 299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Grassi, G. Seravalle, F. Quarti-Trevano, R. Dell'Oro, G. Bolla, and G. Mancia
Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure Patients
Hypertension,
November 1, 2003;
42(5):
873 - 877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. B. Adamson, K. J. Kleckner, W. L. VanHout, S. Srinivasan, and W. T. Abraham
Cardiac Resynchronization Therapy Improves Heart Rate Variability in Patients with Symptomatic Heart Failure
Circulation,
July 22, 2003;
108(3):
266 - 269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J.W. van Kraaij, R. W.M.M. Jansen, F. C.G.J. Sweep, and W. H.L. Hoefnagels
Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function
Eur J Heart Fail,
January 1, 2003;
5(1):
47 - 53.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Latini, S. Masson, I. Anand, D. Judd, A. P. Maggioni, Y.-T. Chiang, M. Bevilacqua, M. Salio, P. Cardano, P. H.J.M. Dunselman, et al.
Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT)
Circulation,
November 5, 2002;
106(19):
2454 - 2458.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Marenzi, G. Lauri, E. Assanelli, M. Grazi, J. Campodonico, G. Famoso, and P. Agostoni
Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure
Eur J Heart Fail,
October 1, 2002;
4(5):
597 - 603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Sivasubramanian, M. L. Coker, K. M. Kurrelmeyer, W. R. MacLellan, F. J. DeMayo, F. G. Spinale, and D. L. Mann
Left Ventricular Remodeling in Transgenic Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor
Circulation,
August 14, 2001;
104(7):
826 - 831.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G. Andreassi, S. Del Ry, C. Palmieri, A. Clerico, A. Biagini, and D. Giannessi
Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones
Eur J Heart Fail,
August 1, 2001;
3(4):
407 - 414.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Rossi, M. Enriquez-Sarano, J. C. Burnett Jr., A. Lerman, M. D. Abel, and J. B. Seward
Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Doppler-echocardiographic study
J. Am. Coll. Cardiol.,
April 1, 2000;
35(5):
1256 - 1262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. P. Dutka, S. Puri, R. Strong, and J. G.F. Cleland
Disruption of the relationship between renin and atrial natriuretic peptide early in the course of ventricular dysfunction
Eur J Heart Fail,
December 17, 1999;
1(4):
371 - 377.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Dibbs, J. Thornby, B. G. White, and D. L. Mann
Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials
J. Am. Coll. Cardiol.,
June 1, 1999;
33(7):
1935 - 1942.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Yamamoto, U. Ikeda, K. Okada, T. Saito, Y. Kawahara, M. Okuda, M. Yokoyama, and K. Shimada
Arginine Vasopressin Increases Nitric Oxide Synthesis in Cytokine-Stimulated Rat Cardiac Myocytes
Hypertension,
November 1, 1997;
30(5):
1112 - 1120.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. R. Benedict, B. Shelton, D. E. Johnstone, G. Francis, B. Greenberg, M. Konstam, J. L. Probstfield, and S. Yusuf
Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction
Circulation,
August 15, 1996;
94(4):
690 - 697.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
G. Grassi, G. Seravalle, B. M. Cattaneo, A. Lanfranchi, S. Vailati, C. Giannattasio, A. Del Bo, C. Sala, G. B. Bolla, M. Pozzi, et al.
Sympathetic Activation and Loss of Reflex Sympathetic Control in Mild Congestive Heart Failure
Circulation,
December 1, 1995;
92(11):
3206 - 3211.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Swedberg, M. R. Bristow, J. N. Cohn, H. Dargie, M. Straub, C. Wiltse, T. J. Wright, and for the Moxonidine Safety and Efficacy (MOXSE) Inv
Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure
Circulation,
April 16, 2002;
105(15):
1797 - 1803.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|